Daily non-political popular news in brief.
Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data
11-13-2006 · EurekAlert!Amgen (NASDAQ: AMGN) announced Enbrel (R) (etanercept) is the first biologic with published data to show sustained improvements in multiple efficacy measures in rheumatoid arthritis patients completing up to nine years of therapy. Current data suggest Enbrel is both effective and safe in long-term RA use, and the new data, presented at the American College of Rheumatology scientific meeting, provide a degree of reassurance that unexpected safety concerns do not appear to develop after nine years of use.
Read more »
Keywords: enbrel, biologic, rheumatoid, arthritis, safety, sustained, efficacy, data, arthriti
« Previous | Next »
Similar news on "Enbrel first biologic with up to 9 years rheumatoid arthritis safety, sustained efficacy data":
- Disability from long-term rheumatoid arthritis reduced with biologic treatment
06-12-2007 · EurekAlert!
New data demonstrating the safety and efficacy of Enbrel (etanercept) in the treatment of rheumatoid arthritis (RA) patients over the long-term were presented today at the EULAR (European League Against Rheumatism) congress (1). Over 2,000 patients receiving this biologic treatment for up to nine years, saw improvements in disability whilst safety was also sustained over the long-term.
Similar news · Read more »
- Enbrel safety data for up to 8 years in patients with juvenile rheumatoid arthritis
06-13-2007 · EurekAlert!
Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced the presentation of additional data that showed that the safety profile of Enbrel was maintained with long-term use in patients with moderate-to-severe juvenile rheumatoid arthritis who completed up to eight years of therapy. The study results will be presented at the European League Against Rheumatism Annual Congress, an international rheumatology meeting, in Barcelona, Spain.
Similar news · Read more »
- Latest data shows MabThera provides significant, sustained relief from symptoms of RA
06-13-2007 · EurekAlert!
New data presented at the EULAR meeting demonstrate that MabThera's effectiveness in relieving patients of the distressing symptoms of rheumatoid arthritis is sustained or further improved with subsequent courses of treatment, as is the number of patients achieving remission. Importantly, the safety profile of MabThera remained unchanged in patients who had received as many as seven courses of treatment at 6-12 month intervals.
Similar news · Read more »
- Half of patients with active early rheumatoid arthritis achieved clinical remission
11-07-2007 · EurekAlert!
Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced that data from a multicenter, randomized, double-blind trial of ENBREL plus methotrexate showed that 50 percent of patients with active early rheumatoid arthritis achieved clinical remission at one year.
Similar news · Read more »
- Phase 3 data show golimumab improved psoriatic arthritis symptoms
11-07-2007 · EurekAlert!
Patients with active psoriatic arthritis receiving monthly subcutaneous injections of golimumab experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest phase 3 biologic study ever completed in subjects with psoriatic arthritis.
Similar news · Read more »
- Enhanced MR-guided focused ultrasound guidelines demonstrate improved efficacy and durability
05-08-2007 · EurekAlert!
Data released today show that MR-guided focused ultrasound is a more effective option for a broader population of uterine fibroid sufferers. In a poster presented today at the American College of Obstetrics and Gynecology annual meeting in San Diego, Phyllis Gee, M.D. of the North Texas Uterine Fibroid Institute in Plano, Texas, showed that women undergoing MRgFUS experience rapid and sustained relief from their condition and have a reduced need for alternative, invasive treatments in the future.
Similar news · Read more »
- TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
01-24-2008 · EurekAlert!
Individuals with the inflammatory bowel disease ulcerative colitis are at increased risk of developing colon cancer. New data have identified a central role for the soluble factor TNF-alpha in the development of colon cancer in mice induced to have inflammatory bowel disease. These data provide clear rationale for the idea that drugs antagonizing TNF-alpha (such as those used to treat rheumatoid arthritis) might reduce the risk of colon cancer in individuals with UC.
Similar news · Read more »
- New study reveals gender disparity in anti-TNF treatment for rheumatoid arthritis
06-14-2007 · EurekAlert!
Findings reported today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain, reveal a treatment disparity between female and male patients with rheumatoid arthritis. Data from a study at the Karolinska Institute, Sweden, show that women receive anti-TNFs -- very effective but expensive modern medications against this disease -- at a higher perceived level of disease activity, and when they are reporting more severe pain than their male counterparts.
Similar news · Read more »
- First prospective study shows improvement of rheumatoid arthritis during pregnancy
06-14-2007 · EurekAlert!
Disease activity in patients with rheumatoid arthritis is significantly reduced during pregnancy, according to new data presented today at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain. In the study, RA improved significantly from the first trimester to the third trimester of the participants' pregnancy and this effect extended into the postpartum stage.
Similar news · Read more »
- Combining medications often best strategy to battle rheumatoid arthritis
11-19-2007 · EurekAlert!
For patients with rheumatoid arthritis, combining one well-known, lower-cost synthetic drug with one of six biologic medications often works best to reduce joint swelling or tenderness, according to a new report by researchers at the RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center.
Similar news · Read more »
